Drug Trial Radar · NCT05507580
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
461
Actual
Start
May 29, 2023
Primary completion
Jul 11, 2024
Study completion Aug 15, 2024
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study evaluates the dosing flexibility of upadacitinib in adult participants with moderate to severe AD. Adverse events and change in the disease activity will be assessed. Upadacitinib is an approved drug for the treatment of moderate to severe/active immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis (UC), Crohn's Disease (CD), and AD. The study is comprised of a 35-day Screening Period, a 12-week double-blind period and a 12-week single-blind period. During the double-blind period, participants are placed in 1 of 2 groups, called treatment arms and will be randomized in a 1:1 ratio to receive upadacitinib. At 12 weeks during the single blind period, participants will be blinded to the upadacitinib dose based on their EASI response and reassigned to in 1 of 4 arms. After the last study visit, there is a 30-day follow-up visit. Approximately 454 adult participants ages 18 to 64 with moderate to severe AD who are candidates for systemic therapy will be enrolled at up to 160 sites worldwide. The study is comprised of a 12-week double-blind period, followed by a 12-week single-blind period. Participants will receive upadacitinib oral tablets once daily for up to 24 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Atopic Dermatitis
Interventions
UpadacitinibDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 24Time frame: Baseline and Week 24
Locations
106 sites in 18 countries. Site status is shown where the registry gives one.
Momentum Clinical Research /ID# 254028
Darlinghurst, New South Wales, Australia
Premier Specialist /ID# 246150
Kogarah, New South Wales, Australia
Veracity Clinical Research /ID# 246154
Woolloongabba, Queensland, Australia
North Eastern Health Specialists /ID# 246153
Campbelltown, South Australia, Australia
Skin Health Institute Inc /ID# 246146
Carlton, Victoria, Australia
CHU de Liege /ID# 245839
Liège, Belgium
Cliniques Universitaires UCL Saint-Luc /ID# 245842
Woluwe-Saint-Lambert, Brussels Capital, Belgium
Grand Hôpital De Charleroi - Notre Dame /ID# 245837
Charleroi, Hainaut, Belgium
AZ Sint-Lucas /ID# 253708
Ghent, Oost-Vlaanderen, Belgium
Dermatologie Maldegem /ID# 245840
Maldegem, Oost-Vlaanderen, Belgium
Medical center Cordis /ID# 253310
Pleven, Bulgaria
Acibadem City Clinic Tokuda University Hospital EAD /ID# 246395
Sofia, Bulgaria
Ambulatory for Specialized Medical Care for skin and venereal diseases /ID# 247027
Sofia, Bulgaria
Medical Center Euroderma /ID# 246736
Sofia, Bulgaria
Medical center EuroHealth /ID# 246305
Sofia, Bulgaria
UMHAT Alexandrovska EAD /ID# 246594
Sofiya, Sofia, Bulgaria
Dermatology Research Institute - Blackfoot Trail /ID# 246703
Calgary, Alberta, Canada
Beacon Dermatology Inc /ID# 246705
Calgary, Alberta, Canada
Rejuvenation Dermatology - Edmonton Downtown /ID# 256790
Edmonton, Alberta, Canada
Alberta DermaSurgery Centre /ID# 247286
Edmonton, Alberta, Canada
Dr. Chih-ho Hong Medical Inc. /ID# 246700
Surrey, British Columbia, Canada
Lynde Institute for Dermatology /ID# 246699
Markham, Ontario, Canada
SKiN Centre for Dermatology /ID# 246702
Peterborough, Ontario, Canada
Private Practice - Dr. Kim Papp Clinical Research /ID# 246698
Waterloo, Ontario, Canada
Beijing Friendship Hospital /ID# 247719
Beijing, Beijing Municipality, China
Peking University Third Hospital /ID# 247842
Beijing, Beijing Municipality, China
Dermatology Hospital of Southern Medical University /ID# 247951
Guangzhou, Guangdong, China
The First Hospital of China Medical University /ID# 247686
Shenyang, Liaoning, China
Huashan Hospital, Fudan University /ID# 247680
Shanghai, Shanghai Municipality, China
Elbe Klinikum Buxtehude /ID# 245626
Buxtehude, Germany
Derma Study Center Friedrichshafen GmbH /ID# 245640
Friedrichshafen, Germany
Universitaetsklinikum Halle (Saale) /ID# 245637
Halle, Germany
Dermatologikum Hamburg /ID# 245635
Hamburg, Germany
Dermatologie Quist-BAG Dres. med. Quist PartG /ID# 245628
Mainz, Germany
Dermatologische Gemeinschaftspraxis Mahlow /ID# 245629
Blankenfelde-Mahlow, Brandenburg, Germany
Klinikum Darmstadt /ID# 247028
Darmstadt, Hesse, Germany
Universitaetsklinikum Frankfurt /ID# 245627
Frankfurt am Main, Hesse, Germany
Fachklinik Bad Bentheim /ID# 245634
Bad Bentheim, Lower Saxony, Germany
Studienzentrum an der Hase GbR Dr. Weyergraf/Dr. Frick/Thomas Heiber /ID# 245636
Bramsche, Lower Saxony, Germany
Universitaetsklinikum Muenster /ID# 245623
Münster, North Rhine-Westphalia, Germany
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.